Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy

Published:2024-06-28 Issue: Volume: Page:
ISSN:2168-8184
Container-title:Cureus
language:en
Short-container-title:

Author:

Akdag Goncagul,Dogan Akif,Yildirim Sedat,Kinikoglu Oguzcan,Mokresh Muhammed Edib,Alomari Omar,Turkoglu Ezgi,Isik Deniz,Sürmeli Heves,Basoglu Tugba,Sever Ozlem N,Odabas Hatice,Yildirim Mahmut E,Turan Nedim

Publisher

Springer Science and Business Media LLC

Reference27 articles.

1. Differences in breast cancer survival by molecular subtypes in the United States;Howlader N;Cancer Epidemiol Biomarkers Prev,2018

2. CDK4/6 inhibition in breast cancer: current practice and future directions;Pernas S;Ther Adv Med Oncol,2018

3. Targeting CDK4 and CDK6 in cancer;Goel S;Nat Rev Cancer,2022

4. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis;Gonzalez-Suarez E;Nature,2010

5. Can we prevent BRCA1-associated breast cancer by RANKL inhibition?;Kotsopoulos J;Breast Cancer Res Treat,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP